large-cap preview stock focu expect set print
chicken-littl emerg infecti diseas threat rise wear crown
svc quick cup global cash-to-card tailwind
larg cap specialti pharma upcom kol call lunch event
inc one pill make larger one pill make small still stand tall upjohn spin-out
proteostasi inc spell option without pti feedback compani kol event
selecta bioscienc inc think immtor platform underappreci potenti gout gene therapi initi
corpor total knee mako placement neurotech drive strong close
click headlin titl taken report summari click titl summari open full pdf report
disclosur section may found page
page
think immtor platform underappreci potenti gout gene therapi initi
invest summari initi overweight pt radar stori de-risk phase readi asset see
broad potenti immtor platform enabl gene therapi re-dos selecta clinical-stag compani platform
call immtor design prevent immunogen induc antigen specif toler immunogen anti-drug
antibodi key factor lower efficaci caus safeti issu anaphylaxi sever inject reaction
therapeut lead program use immtor gout think data show clear proof concept
platform also support market opportun gout guid enter phase year
compani also studi immtor combin gene therapi program order potenti enabl gene therapi
re-dos anti-capsid antibodi increas efficaci
see clinic profil meaning superior versu approv product krystexxa interim data phase
compar head-to-head think demonstr clear efficaci safeti benefit standard care krystexxa
think krystexxa efficaci limit high immunogen anti-drug-antibodi think compar
interim data dose find data show higher respons rate lower flare rate improv toler much
lower sae rate vs krystexxa think full compar data draw investor attent
asset importantli think lower anti-drug antibodies/ada better profil key proof
concept immtor platform
see peak sale gout vs market cap took detail look gout market
convict high unmet need often debilit diseas think better treatment
grow market proport treat patient gout uncontrol serum uric acid level mg/dl uric
acid crystal continu deposit caus signific clinic complic requir emerg manag gout
flare surgeri reduc tophi impact roughli peopl us think krystexxa uptak
limit estim popul toler profil high inject site reaction increas
gout flare initi though horizon cover chen ow see growth peak potenti sale
think immtor platform broad potenti improv efficacy/safeti mani therapeut immtor use
proprietari nanoparticl deliv rapamycin instead system immun suppress approach
directli present rapamycin antigen present cell dendrit cell importantli think shown
clear clinic proof concept immtor platform notabl show dose-depend decreas ada anti-drug
antibodi format combin immtor
gene therapi key piec option immtor platform potenti enabl gene therapi re-dos
selb also portfolio gene therapi program studi immtor wholli own collabor
first program enter clinic guid collabor askbio privat selecta
bioscienc share roughli half right immunogen anti-capsid antibodi consid key barrier re-
dose immtor combin could lower anti-capsid anti-aav antibodi titer enabl re-dos
host kol call gout friday januari et discuss opportun gout
dial us toll-fre password gout
large-cap preview stock focu expect set print
invest summari biotech earn start thursday us await mani compani set
import expect large-cap coverag think intrigu guidanc updat
 ow new spinraza competit swing factor set expect aducanumab
focu expect limit commentari vertex trikafta script trend look robust focus
guidanc manag set cf busi like robust launch horizon reiter
top large-cap pick pg report detail large-cap earn preview
director equiti research
disclosur section may found page
page
chicken-littl emerg infecti diseas threat rise wear crown
invest summari imagin emerg infecti diseas increasingli common like driven
facil intern travel increas popul densiti rural area exposur wild thing greater media
awar outbreak histor close countri exhibit fact third coronaviru follow
sars-cov mers-cov cross speci infect human last two decad exhibit govern
variou privat organ increas fund vaccin develop curb spread infecti diseas
includ two prior coronavirus especi follow recent ebola outbreak invest help
pave way versatil vaccin technolog expediti creat therapeut candid emerg
threat interest
notabl believ two compani current coverag technolog platform inovio ow pt
perhap even pt appear well-posit execut vaccin develop due year
experi importantli compani current studi lead asset rais awar
specif therapeut candid even broadli underli platform late-stag candid includ
inovio hpv-driven cervic dysplasia data novavax nanoflu influenza data
posit data program clinic experi garner within believ execut risk inovio
perhap may seen rel lower emerg threat go forward said given inher
technolog advantag perceiv dna-bas vaccin cepi fund posit clinic experi
coronaviru mer believ inovio front-runn broadli applic platform rapidli develop
therapeut vaccin deal emerg infecti diseas threat chicken littl believ
ncov anoth possibl increas number threat futur
see averag timelin approv year potenti acceler case vaccin
rapidli spread world-wide base due dilig believ hand deck approach deploy
mani stakehold work expediti get vaccin approv includ physician scientist drug develop fund
organ regulatori author
view key take-away inovio broad clinic experi respect platform
exhibit respect advanc sever candid target variou virus clinic develop
includ studi believ reduc execut risk inovio lead candid two studi
hpv-depend cervic dysplasia first studi read therapeut vaccin
program see hpv clear infecti diseas threat certain similar recent emerg id outbreak
includ abil transmit diseas even non-symptomat thu efficaci reveal trial may read
potenti platform broadli well candid lead candid nanoflu recent
grant track design fda non-inferior immunogen trial licens compar
fluzon order obtain initi licensur data expect commit conduct post-licensur efficaci
head research sale
head equiti sale trade
head equiti trade
mike cornett us head trade
disclosur section may found page
financials/reit industri
page
total knee mako placement neurotech drive strong close
invest summari reiter neutral rate maintain pt report anoth healthi print
revenu beat factset consensu ep beat street organ revenu growth
top end full year guidanc strength broad-bas across
busi total knee growth impress mako placement us neurotech growth high teen organ
stood introduc organ revenu growth guidanc bracket street expect provid
initi guidanc last year ceo kevin lobo state felt good busi time
last year suggest guidanc may conserv expect continu execut impress level
continu believ difficult significantli outperform high investor expect addit
think could hesit learn detail condit close acquisit
potenti financi impact updat model includ contribut begin base
assum close end
broad-bas strength drive top line guidanc consensu revenu beat street
expect strong perform across busi organ growth broad-bas
medsurg ortho neurotechnolog spine post solid growth us knee growth
particularli impress quarter reflect strong demand mako tka print cementless knee
geograph strong organ growth us ou strong dd growth emerg
organ growth guidanc appear conserv introduc organ revenu growth guidanc
midpoint factset consensu ep guidanc consensu
midpoint hit goal annual oper margin improv
expect hit goal given margin dilut wright acquisit
impress placement metric demonstr continu mako momentum sold mako system global
us ever quarter util improv doubl digit sequenti
total knee procedur perform continu see grow demand mako hip
applic growth hip procedur oversea see japan signific near-
term opportun robot place recent gain japanes approv mako partial knee
indic ad indic total knee hip
updat estim reflect quarter contribut ad estim
estim new revenu estim vs prior includ one
quarter contribut rais ep estim
valuat price target base price-to-earnings multipl ep estim
disclosur section may found page
page
one pill make larger one pill make small still stand tall upjohn spin-
invest summari maintain ow rate pt despit ep miss earn
miss concern growth prospect overdon view spin-out upjohn
confid meet revenu compound-annual-growth-rate industri averag sale growth
driven solid execut innov therefor expect upward earn revis multipl expans
move share higher
report adjust dilut ep lower factset higher estim
present sale ep guidanc adjust dilut ep factset
respect midpoint new revenu guidanc rang impli yoy oper growth
guidanc assum full-year contribut biopharma upjohn share repurchas per
profil compani vastli differ follow upjohn separ result share repurchas
list capit alloc prioriti come behind dividend re-invest pipelin clinical-stag
busi develop remain author give flexibl opportunist market condit
warrant adjust financi model report compani outlook increas
deliv stand-alone guidanc provid preliminari profil new
time point pro-forma revenu ibt margin rang oper cash flow
stand-alone revenu compound-annual-growth-rate without upjohn expect factset forecast
year revenu compound-annual-growth-rate upjohn today promis provid upsid initi guidanc
expect revenu ibt margin adjust dilut ep street
expect oper cash flow guidanc revenu compound-annual-growth-rate remain
takeaway report support posit thesi full-year revenu reflect
oper declin exclud impact consum healthcar revenu increas oper
oper growth biopharma primarili driven ibranc eliqui xeljanz vyndaqel well
oper growth emerg market oper declin upjohn primarili due loe
lyrica revenu reflect oper declin exclud impact consum healthcar
revenu declin oper oper growth biopharma oper declin
upjohn paid dividend enact share repurchas remain
share repurchas author vyndaqel/vyndamax global revenu driven
launch oper growth intern market full-year upjohn revenu china grew
oper primarili driven product affect vbp implement includ viagra celebrex zoloft
lyrica well lipitor norvasc provinc volume-bas procur vbp program
implement
disclosur section may found page
page
invest summari today meso report quarterli cash flow oper highlight
compani strong execut quarter underscor ow rate price target meso share
think meso late-stag pipelin allogen off-the-shelf cellular drug inflammatori diseas underappreci
expect busi year compani multipl import late-stag data readout expect pipelin
potenti us launch ryoncil therefor upward earn revis drive meso stock higher
highlight includ clinic efficaci safeti data file ryoncil compani roll
bla includ analys children agvhd receiv ryoncil across three separ studi
new data control pediatr subject contemporan databas magic result demonstr
effect ryoncil patient popul particular efficaci surviv benefit patient
sever form agvhd approv meso plan us launch ryoncil meso phase trial
evalu revascor advanc chronic heart failur surpass number primari endpoint event requir
trial complet complet surviv patient follow least month mean
follow period approxim month result pivot trial expect read
dmc overse revascor phase trial held final schedul meet decemb
recommend trial continu plan dmc review avail data random
patient includ compon trial primari secondari endpoint safeti data continu
oper progress strateg partnership heart failur china privat
clbp grnenthal europ includ plan leverag us phase trial data readout meso continu
activ discuss addit pharmaceut compani regard potenti global region
strateg partnership hand end quarter next
month meso may access addit exist financ facil
meso report revenu sale temcel japan quarter end
in-lin factset consensu reflect growth compar quarter roll
month basi revenu increas rel prior correspond period
total cash receipt oper activ compos up-front
mileston payment grnenthal strateg partnership royalti meso total cash
payment oper activ reduc rel compar quarter
reflect reduc spend clinic program partial off-set invest manufactur
commerci activ expect us launch ryoncil
valuat arriv price target meso share use blend ev/ebitda dcf
disclosur section may found page
page
spell option without pti feedback compani kol event
invest summari reiter ow rate price target pti afternoon attend kol event
host compani new york kol dr damian downey clinic senior lectur respiratori medicin
queen univers belfast one author trikafta vertex -vrtx ow young phase lancet public
featur homozyg mutat patient cystic fibrosi cf takeaway event despit
approv therapi physician crave option patient effect observ and/or
elig futur precis medicin import consider determin treatment might
appropri patient begin comment along survey compani conduct
note rang improv across trikafta make us feel confid second entrant would
welcom cf patient
compar pti trial appl pear kol note patient vertex proteostasi
triplet studi repres differ dataset thu note could challeng compar efficaci measur
across trial specif focus age differ vertex studi includ patient age
wherea proteostasi studi patient age dr downey note would expect see stronger
result younger patient lung may less damag also discuss patient treat
previou cftr modul may slower respons switch new therapi key differenti
found interest note adher could import practic compar day trikafta vs
third-parti physician survey support room second entrant view proteostasi conduct third-parti
survey pulmonologist patient trikafta day note unawar
specif question ask survey time point number measur taken across
patient physician note gener satisfact trikafta limit includ experienc
improv experienc improv patient
discontinu treatment primarili due toler issu advers effect and/or access issu physician
survey well dr downey also discuss import observ durabl take survey
initi launch support strong efficaci profil trikafta leav room second entrant patient
respond well and/or toler treatment model assum market penetr
proteostasi signific pay cut drug price still equat sale million
futur person medicin help predict efficaci kol note precis medicin could
import tool predict efficaci patient approach could help determin might respond includ
patient ultra-rar mutat approv therapi exist note necessarili
perfect tool determin may respond understand recruit choic trial near complet
dose could begin potenti data readout previous announc compani note
studi could serv basi file believ could repres million market opportun
disclosur section may found page
